TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma
Abstract Objective Multiple myeloma is a haematological malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Development of resistance and minimal residual disease remain challenging in the treatment of multiple myeloma. Transforming growth factor-β activated kina...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-11-01
|
| Series: | BMC Research Notes |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13104-022-06237-3 |
| _version_ | 1797986866782273536 |
|---|---|
| author | Erling Håland Ingrid Nyhus Moen Esten N. Vandsemb Kristian K. Starheim |
| author_facet | Erling Håland Ingrid Nyhus Moen Esten N. Vandsemb Kristian K. Starheim |
| author_sort | Erling Håland |
| collection | DOAJ |
| description | Abstract Objective Multiple myeloma is a haematological malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Development of resistance and minimal residual disease remain challenging in the treatment of multiple myeloma. Transforming growth factor-β activated kinase 1 (TAK1) has recently gained attention as a potential drug target in multiple myeloma. This study aimed at determining the in vivo effects of TAK1-inhibitors in a Vκ*MYC multiple myeloma mouse model. Results We treated mice carrying Vκ*MYC multiple myeloma cells with the TAK1-inhibitors 5Z-7-oxozeaenol and NG25. There were tendencies towards increased survival for both inhibitors, but only NG25 prolonged survival significantly. However, this effect was limited, and no differences in disease burden were observed for any of the treatments. In conclusion, although TAK1-inhibitors might prolong survival somewhat, they do not prevent disease in the Vκ*MYC mouse model of multiple myeloma. |
| first_indexed | 2024-04-11T07:39:46Z |
| format | Article |
| id | doaj.art-89bb78f60f6f4222966d3218dc6a3f63 |
| institution | Directory Open Access Journal |
| issn | 1756-0500 |
| language | English |
| last_indexed | 2024-04-11T07:39:46Z |
| publishDate | 2022-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Research Notes |
| spelling | doaj.art-89bb78f60f6f4222966d3218dc6a3f632022-12-22T04:36:38ZengBMCBMC Research Notes1756-05002022-11-011511510.1186/s13104-022-06237-3TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myelomaErling Håland0Ingrid Nyhus Moen1Esten N. Vandsemb2Kristian K. Starheim3CEMIR Centre of Molecular Inflammation Research, IKOM, NTNUCEMIR Centre of Molecular Inflammation Research, IKOM, NTNUDepartment of Clinical and Molecular Medicine, NTNUCEMIR Centre of Molecular Inflammation Research, IKOM, NTNUAbstract Objective Multiple myeloma is a haematological malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Development of resistance and minimal residual disease remain challenging in the treatment of multiple myeloma. Transforming growth factor-β activated kinase 1 (TAK1) has recently gained attention as a potential drug target in multiple myeloma. This study aimed at determining the in vivo effects of TAK1-inhibitors in a Vκ*MYC multiple myeloma mouse model. Results We treated mice carrying Vκ*MYC multiple myeloma cells with the TAK1-inhibitors 5Z-7-oxozeaenol and NG25. There were tendencies towards increased survival for both inhibitors, but only NG25 prolonged survival significantly. However, this effect was limited, and no differences in disease burden were observed for any of the treatments. In conclusion, although TAK1-inhibitors might prolong survival somewhat, they do not prevent disease in the Vκ*MYC mouse model of multiple myeloma.https://doi.org/10.1186/s13104-022-06237-3Multiple myelomaTAK1Haematological malignancy5Z-7NG25 |
| spellingShingle | Erling Håland Ingrid Nyhus Moen Esten N. Vandsemb Kristian K. Starheim TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma BMC Research Notes Multiple myeloma TAK1 Haematological malignancy 5Z-7 NG25 |
| title | TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma |
| title_full | TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma |
| title_fullStr | TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma |
| title_full_unstemmed | TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma |
| title_short | TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma |
| title_sort | tak1 inhibitors did not reduce disease burden in a vκ myc model of multiple myeloma |
| topic | Multiple myeloma TAK1 Haematological malignancy 5Z-7 NG25 |
| url | https://doi.org/10.1186/s13104-022-06237-3 |
| work_keys_str_mv | AT erlinghaland tak1inhibitorsdidnotreducediseaseburdeninavkmycmodelofmultiplemyeloma AT ingridnyhusmoen tak1inhibitorsdidnotreducediseaseburdeninavkmycmodelofmultiplemyeloma AT estennvandsemb tak1inhibitorsdidnotreducediseaseburdeninavkmycmodelofmultiplemyeloma AT kristiankstarheim tak1inhibitorsdidnotreducediseaseburdeninavkmycmodelofmultiplemyeloma |